Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2020

Open Access 01-10-2020 | Levodopa | Review

Medical Management and Prevention of Motor Complications in Parkinson’s Disease

Authors: Stephen D. Aradi, Robert A. Hauser

Published in: Neurotherapeutics | Issue 4/2020

Login to get access

Abstract

Levodopa is the most effective medication for the treatment of the motor symptoms of Parkinson’s disease. However, over time, the clinical response to levodopa becomes complicated by a reduction in the duration and reliability of motor improvement (motor fluctuations) and the emergence of involuntary movements (levodopa-induced dyskinesia). Strategies that have been attempted in an effort to delay the development of these motor complications include levodopa sparing and continuous dopaminergic therapy. Once motor complications occur, a wide array of medical treatments is available to maximize motor function through the day while limiting dyskinesia. Here, we review the clinical features, epidemiology, and risk factors for the development of motor complications, as well as strategies for their prevention and medical management.
Appendix
Available only for authorised users
Literature
1.
Postuma RB, Berg D, Stern M, et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef
2.
Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F (2018) The spectrum of “off” in Parkinson’s disease: What have we learned over 40 years? Parkinsonism Relat Disord 51:9–16PubMedCrossRef
3.
Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 20 Suppl 11:S11–6PubMedCrossRef
4.
Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, Factor SA (2000) A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 23:75–81PubMedCrossRef
5.
Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30:80–89PubMedCrossRef
6.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491PubMedCrossRef
7.
Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov Disord 9:2–12PubMedCrossRef
8.
Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D-”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52:163–174PubMed
9.
Grötzsch H, Sztajzel R, Burkhard PR (2007) Levodopa-induced ocular dyskinesia in Parkinson’s disease. Eur J Neurol 14:1124–1128PubMedCrossRef
10.
LeWitt PA (1998) Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson’s disease. Mov Disord 13:731–734PubMedCrossRef
11.
Rice JE, Antic R, Thompson PD (2002) Disordered respiration as a levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord 17:524–527PubMedCrossRef
12.
Carecchio M, Collini A, Comi C, Cantello R, Bhatia KP, Monaco F (2010) Levodopa-induced belly dancer’s dyskinesias in Parkinson’s disease: report of one case. Mov Disord 25:1760–1762PubMedCrossRef
13.
14.
Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR (2011) Management of punding in Parkinson’s disease: an open-label prospective study. J Neurol 258:656–660PubMedCrossRef
15.
Kashihara K, Imamura T (2008) Amantadine may reverse punding in Parkinson’s disease--observation in a patient. Mov Disord 23:129–130PubMedCrossRef
16.
Aquino CC, Celso de Castro P, Doná F, Medeiros L, Silva SMCA, Borges V, Ferraz HB (2013) Reduction in Parkinson’s disease therapy improved punding but not feeling of presence. J Neuropsychiatr Clin Neurosci 25:E43–4CrossRef
17.
Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ (2006) Punding and dyskinesias. Mov Disord 21:2214–2217PubMedCrossRef
18.
Yoon WT (2018) Comparison of dystonia between Parkinson’s disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. Neurol Neurochir Pol 52:48–53PubMedCrossRef
19.
Stefanova N, Bücke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178PubMedCrossRef
20.
Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844PubMedCrossRef
21.
Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458PubMedCrossRef
22.
Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1:345–349PubMedCrossRef
23.
Stocchi F, Antonini A, Barone P, et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204–211PubMedCrossRef
24.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508PubMedCrossRef
25.
Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE (2006) Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 63:205–209PubMedCrossRef
26.
Kelly MJ, Lawton MA, Baig F, Ruffmann C, Barber TR, Lo C, Klein JC, Ben-Shlomo Y, Hu MT (2019) Predictors of motor complications in early Parkinson’s disease: A prospective cohort study. Mov Disord 34:1174–1183PubMedPubMedCentralCrossRef
27.
Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63:1756–1760PubMedCrossRef
28.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28:1064–1071PubMedCrossRef
29.
Mizuno Y, Shimoda S, Origasa H (2018) Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs. J Neural Transm 125:35–43PubMedCrossRef
30.
Chaudhuri KR, Jenner P, Antonini A (2019) Should there be less emphasis on levodopa-induced dyskinesia in Parkinson’s disease? Mov Disord 34:816–819PubMedCrossRef
31.
Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA (2020) Dyskinesia matters. Mov Disord 35:392–396PubMedCrossRef
32.
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409–2417PubMedCrossRef
33.
Parkinson Study Group CALM Cohort Investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563–570CrossRef
34.
Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study GroupJAMA 284:1931–1938CrossRef
35.
Holloway RG, Shoulson I, Fahn S, et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053PubMed
36.
PD MED Collaborative Group (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196–1205CrossRef
37.
Verschuur CVM, Suwijn SR, Boel JA, et al (2019) Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. N Engl J Med 380:315–324PubMedCrossRef
38.
Cilia R, Akpalu A, Sarfo FS, et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137:2731–2742PubMedPubMedCentralCrossRef
39.
Olanow CW, Obeso JA, Stocchi F (2006) Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2:382–392PubMedCrossRef
40.
Ray Chaudhuri K, Poewe W, Brooks D (2018) Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features. Mov Disord 33:909–919PubMedCrossRef
41.
Picconi B, Hernández LF, Obeso JA, Calabresi P (2018) Motor complications in Parkinson’s disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord 33:867–876PubMedCrossRef
42.
Olanow CW, Kieburtz K, Odin P, et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149PubMedCrossRef
43.
Antonini A, Nitu B (2018) Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm 125:1131–1135PubMedCrossRef
44.
Katzenschlager R, Poewe W, Rascol O, et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759PubMedCrossRef
45.
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27PubMedCrossRef
46.
van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P (2018) Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease. J Parkinsons Dis 8:S65–S72PubMedPubMedCentralCrossRef
47.
Freitas ME, Ruiz-Lopez M, Fox SH (2016) Novel Levodopa Formulations for Parkinson’s Disease. CNS Drugs 30:1079–1095PubMedCrossRef
48.
Hsu A, Yao H-M, Gupta S, Modi NB (2015) Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). J Clin Pharmacol 55:995–1003PubMedPubMedCentralCrossRef
49.
Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O’Connell MJ, Modi NB, Yao H-M, Kell SH, Gupta SK (2011) Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov Disord 26:2246–2252PubMedCrossRef
50.
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O’Connell M, Gupta S, IPX066 ADVANCE-PD investigators (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 12:346–356PubMedCrossRef
51.
Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S (2014) Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 20:1335–1340PubMedCrossRef
52.
Yao H-M, Hsu A, Gupta S, Modi NB (2016) Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers. Clin Neuropharmacol 39:10–17PubMedPubMedCentralCrossRef
53.
54.
Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S (2018) Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson’s Disease with Motor Fluctuations. Parkinsons Dis 2018:9763057PubMedPubMedCentral
55.
Hauser RA (2015) How to dose carbidopa and levodopa extended release capsules (Rytary). Clin Med J 1:34–37
56.
Espay AJ, Pagan FL, Walter BL, et al (2017) Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract 7:86–93PubMedPubMedCentralCrossRef
57.
Pahwa R, Factor SA, Lyons KE, et al (2006) Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983–995PubMedCrossRef
58.
Jankovic J, Schwartz K, Vander Linden C (1989) Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 4:303–309PubMedCrossRef
59.
Hutton JT, Morris JL, Román GC, Imke SC, Elias JW (1988) Treatment of chronic Parkinson’s disease with controlled-release carbidopa/levodopa. Arch Neurol 45:861–864PubMedCrossRef
60.
Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA (1988) Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin Proc 63:876–886PubMedCrossRef
61.
Lieberman A, Gopinathan G, Miller E, Neophytides A, Baumann G, Chin L (1990) Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson’s disease. Eur Neurol 30:75–78PubMedCrossRef
62.
63.
Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI (2016) Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease Sci Transl Med 8:360ra136PubMedCrossRef
64.
LeWitt PA, Hauser RA, Grosset DG, et al (2016) A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord 31:1356–1365PubMedCrossRef
65.
LeWitt PA, Hauser RA, Pahwa R, et al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18:145–154PubMedCrossRef
66.
Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-Ebo DM, Zhao P, Oh C (2019) Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism Relat Disord 64:175–180PubMedCrossRef
67.
LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H (2018) Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson’s Disease. J Aerosol Med Pulm Drug Deliv 31:155–161PubMedPubMedCentralCrossRef
68.
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C (2020) Inhaled levodopa in Parkinson’s disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord 71:4–10PubMedCrossRef
69.
70.
Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence-Based Medicine Committee (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33:1248–1266PubMedCrossRef
71.
Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D (1996) Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 19:234–245PubMedCrossRef
72.
Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study GroupNeurology 51:1057–1062PubMedCrossRef
73.
Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68:1108–1115PubMedCrossRef
74.
75.
76.
Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162–168PubMedCrossRef
77.
Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord 20:602–610PubMedCrossRef
78.
Schapira AHV, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W, Pramipexole ER Studies Group (2011) Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77:767–774PubMedCrossRef
79.
80.
81.
LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262–1267PubMedCrossRef
82.
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513–520PubMedCrossRef
83.
LeWitt PA, Boroojerdi B, Surmann E, Poewe W, SP716 Study Group, SP715 Study Group (2013) Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 120:1069–1081PubMedCrossRef
84.
85.
Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs 33:905–918PubMedPubMedCentralCrossRef
86.
Kempster PA, Frankel JP, Stern GM, Lees AJ (1990) Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry 53:1004–1007PubMedPubMedCentralCrossRef
87.
Merello M, Pikielny R, Cammarota A, Leiguarda R (1997) Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson’s disease patients: a double-blind single-dose study. Clin Neuropharmacol 20:165–167PubMedCrossRef
88.
Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403–406PubMedCrossRef
89.
Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 53:96–101PubMedPubMedCentralCrossRef
90.
Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM (1993) Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 8:165–170PubMedCrossRef
91.
Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA (2001) A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58:1385–1392PubMedCrossRef
92.
Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH, APO302 Study Investigators (2007) Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 13:93–100PubMedCrossRef
93.
Pahwa R, Koller WC, Trosch RM, Sherry JH, APO303 Study Investigators (2007) Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 258:137–143PubMedCrossRef
94.
Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F (2017) Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson’s Disease. Mov Disord Clin Pract 4:78–83PubMedCrossRef
95.
Hauser RA, Isaacson S, Clinch T, Tigan/Apokyn Study Investigators (2014) Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 20:1171–1176PubMedCrossRef
96.
Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T (2015) Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol 38:89–103PubMed
97.
98.
99.
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A (2016) Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 31:1366–1372PubMedCrossRef
100.
101.
Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH (2009) A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 8:929–937PubMedCrossRef
102.
Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A (1993) Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 8:298–304PubMedCrossRef
103.
Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P (1995) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253–262PubMedPubMedCentralCrossRef
104.
Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs 59:1233–1250PubMedCrossRef
105.
Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145–156PubMedCrossRef
106.
Sêdek G, Jorga K, Schmitt M, Burns RS, Leese P (1997) Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 20:531–541PubMedCrossRef
107.
(1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 42:747–755
108.
Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, Celomen Study Group (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105:245–255PubMedCrossRef
109.
Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study GroupNeurology 51:1309–1314PubMedCrossRef
110.
Brusa L, Bassi A, Lunardi G, Fedele E, Peppe A, Stefani A, Pasqualetti P, Stanzione P, Pierantozzi M (2004) Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. Eur J Neurol 11:593–606PubMedCrossRef
111.
112.
Rocha J-F, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P (2014) Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70:1059–1071PubMedCrossRef
113.
Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165PubMedCrossRef
114.
Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha J-F, McCrory M, Soares-da-Silva P, BIPARK-2 Study Investigators (2017) Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 74:197–206PubMedCrossRef
115.
Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O (2018) Opicapone for the treatment of Parkinson’s disease: A review of a new licensed medicine. Mov Disord 33:1528–1539PubMedCrossRef
116.
Lees A, Ferreira JJ, Rocha J-F, Rascol O, Poewe W, Gama H, Soares-da-Silva P (2019) Safety Profile of Opicapone in the Management of Parkinson’s Disease. J Parkinsons Dis 9:733–740PubMedCrossRef
117.
118.
Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49:1066–1071PubMedCrossRef
119.
Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63:421–428PubMedPubMedCentralCrossRef
120.
Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 55:1089–1095PubMedCrossRef
121.
Olanow CW (2000) Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 57:263–267PubMedCrossRef
122.
Olanow CW, Watkins PB (2007) Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol 30:287–294PubMedCrossRef
123.
Eggert K, Oertel WH, Lees AJ, German Competence Network on Parkinson’s disease (2014) Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study. Clin Neuropharmacol 37:1–5
124.
125.
Entacapone to Tolcapone Switch Study Investigators (2007) Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 22:14–19CrossRef
126.
Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L (2001) Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur Neurol 46:11–16PubMedCrossRef
127.
Lees AJ (2008) Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson’s disease. CNS Neurosci Ther 14:83–93PubMedPubMedCentralCrossRef
128.
Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha J-F, Keller B, Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90:e1849–e1857PubMedCrossRef
129.
Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, TC-INIT Study Group (2005) Treatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53:197–202PubMedCrossRef
130.
Lyons KE, Pahwa R (2006) Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. Clin Neuropharmacol 29:73–76PubMedCrossRef
131.
Myllylä V, Haapaniemi T, Kaakkola S, et al (2006) Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand 114:181–186PubMedCrossRef
132.
133.
Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease. Clin Ther 29:1825–1849PubMedCrossRef
134.
deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators (2006) Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21:1716–1721PubMedCrossRef
135.
Oreland L, Jossan SS, Hartvig P, Aquilonius SM, Långström B (1990) Turnover of monoamine oxidase B (MAO-B) in pig brain by positron emission tomography using 11C-L-deprenyl. J Neural Transm Suppl 32:55–59PubMed
136.
Mahmood I (1997) Clinical pharmacokinetics and pharmacodynamics of selegiline. An updateClin Pharmacokinet 33:91–102PubMedCrossRef
137.
Freedman NMT, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, Ehrlich D, Chisin R (2005) In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med 46:1618–1624PubMed
138.
Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G, Neophytides AN, Foo SH, Duvoisin RC (1988) Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol 11:45–55PubMedCrossRef
139.
Golbe LI, Duvoisin RC (1987) Double-blind trial of R-(-)-deprenyl for the “on-off” effect complicating Parkinson’s disease. J Neural Transm Suppl 25:123–129PubMed
140.
Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study Group (2004) Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19:426–432PubMedCrossRef
141.
Ondo WG, Sethi KD, Kricorian G (2007) Selegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptoms. Clin Neuropharmacol 30:295–300PubMedCrossRef
142.
Lew MF, Pahwa R, Leehey M, Bertoni J, Kricorian G, Zydis Selegiline Study Group (2007) Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of “off” episodes in patients with Parkinson’s disease. Curr Med Res Opin 23:741–750PubMedCrossRef
143.
144.
145.
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954PubMedCrossRef
146.
Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241–248CrossRef
147.
148.
Müller T, Foley P (2017) Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clin Pharmacokinet 56:251–261PubMedCrossRef
149.
Borgohain R, Szasz J, Stanzione P, et al (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237PubMedCrossRef
150.
Borgohain R, Szasz J, Stanzione P, et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280PubMedCrossRef
151.
Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol 74:216–224PubMedCrossRef
152.
153.
Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, Japan Zonisamide on PD Study Group (2015) Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study. Mov Disord 30:1343–1350PubMedCrossRef
154.
Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group (2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68:45–50PubMedCrossRef
155.
Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41:397–399PubMedCrossRef
156.
Murata M (2004) Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr Pharm Des 10:687–693PubMedCrossRef
157.
158.
Kase H (2001) New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 65:1447–1457PubMedCrossRef
159.
Ochi M, Shiozaki S, Kase H (2004) Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson’s disease. Neuroscience 127:223–231PubMedCrossRef
160.
Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673–1677PubMedCrossRef
161.
Kanda T, Tashiro T, Kuwana Y, Jenner P (1998) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9:2857–2860PubMedCrossRef
162.
Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507–513PubMedCrossRef
163.
LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM, 6002-US-005 Study Group (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295–302PubMedCrossRef
164.
Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-013 Study Group (2008) Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 23:2177–2185PubMedCrossRef
165.
Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 25:1437–1443PubMedCrossRef
166.
Mizuno Y, Kondo T, Japanese Istradefylline Study Group (2013) Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord 28:1138–1141PubMedPubMedCentralCrossRef
167.
Takahashi M, Fujita M, Asai N, Saki M, Mori A (2018) Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother 19:1635–1642PubMedCrossRef
168.
169.
Fox SH (2013) Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs 73:1405–1415PubMedCrossRef
170.
Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586–2588PubMedCrossRef
171.
Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50:1323–1326PubMedCrossRef
172.
Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56:1383–1386PubMedCrossRef
173.
Snow BJ, Macdonald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23:82–85PubMedCrossRef
174.
Luginger E, Wenning GK, Bösch S, Poewe W (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 15:873–878PubMedCrossRef
175.
Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study Group (2010) Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One 5:e15298PubMedPubMedCentralCrossRef
176.
Ory-Magne F, Corvol J-C, Azulay J-P, et al (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300–307PubMedCrossRef
177.
Wolf E, Seppi K, Katzenschlager R, et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord 25:1357–1363PubMedCrossRef
178.
Oertel W, Eggert K, Pahwa R, et al (2017) Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord 32:1701–1709PubMedPubMedCentralCrossRef
179.
Pahwa R, Tanner CM, Hauser RA, et al (2017) ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 74:941–949PubMedPubMedCentralCrossRef
180.
Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R (2018) Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs 32:387–398PubMedPubMedCentralCrossRef
181.
Hauser RA, Kremens DE, Elmer LW, Kreitzman DL, Walsh RR, Johnson R, Howard R, Nguyen JT, Patni R (2019) Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 9:591–600PubMedPubMedCentralCrossRef
182.
183.
184.
deVries T, Dentiste A, Di Lea C, Pichette V, Jacobs D (2019) Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets. CNS Drugs 33:783–789PubMedPubMedCentralCrossRef
185.
Arevalo GJ, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson’s disease: a preliminary study. Mov Disord 8:349–354PubMedCrossRef
186.
Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y (1997) Low-dose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48:658–662PubMedCrossRef
187.
Bennett JP Jr, Landow ER, Schuh LA (1993) Suppression of dyskinesias in advanced Parkinson’s disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 43:1551–1555PubMedCrossRef
188.
Bennett JP Jr, Landow ER, Dietrich S, Schuh LA (1994) Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 9:409–414PubMedCrossRef
189.
Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C (1998) Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 97:295–299PubMedCrossRef
190.
Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381–388PubMedCrossRef
191.
Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 65:709–716PubMedPubMedCentralCrossRef
192.
Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci 22:93–94PubMedCrossRef
193.
Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17:1235–1241PubMedCrossRef
194.
García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136PubMedCrossRef
195.
Drapier S, Gillioz A-S, Leray E, Péron J, Rouaud T, Marchand A, Vérin M (2012) Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 18:40–44PubMedCrossRef
196.
Kimber TE, Fang J, Huddy LJ, Thompson PD (2017) Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J 47:570–573PubMedCrossRef
197.
Martinez-Martin P, Reddy P, Katzenschlager R, et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30:510–516PubMedCrossRef
198.
Drapier S, Eusebio A, Degos B, et al (2016) Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol 263:1111–1119PubMedCrossRef
199.
Borgemeester RWK, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord 23:17–22PubMedCrossRef
200.
Sesar Á, Fernández-Pajarín G, Ares B, Rivas MT, Castro A (2017) Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. J Neurol 264:946–954PubMedCrossRef
201.
Dafsari HS, Martinez-Martin P, Rizos A, et al (2019) EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord 34:353–365PubMedCrossRef
202.
Borgemeester RWK, Lees AJ, van Laar T (2016) Parkinson’s disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism Relat Disord 27:35–40PubMedCrossRef
203.
Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144–1148PubMedCrossRef
204.
Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131–1136PubMedCrossRef
205.
Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson’s disease: response to intravenous infusion of levodopa. Lancet 2:412–415PubMedCrossRef
206.
Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI (1998) Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease. Mov Disord 13:336–338PubMedCrossRef
207.
Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20:262–265PubMedCrossRef
208.
Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23:589–595PubMedCrossRef
209.
Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius S-M (2003) Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26:156–163PubMedCrossRef
210.
Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease--long-term experience. Acta Neurol Scand 104:343–348PubMedCrossRef
211.
Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius S-M, Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223PubMedCrossRef
212.
Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P (2008) Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151–166PubMedCrossRef
213.
Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22:1145–1149PubMedCrossRef
214.
Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol 21:312–318PubMedCrossRef
215.
Zibetti M, Merola A, Ricchi V, et al (2013) Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol 260:105–114PubMedCrossRef
216.
Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J (2015) Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis 5:165–174PubMedCrossRef
217.
Antonini A, Fung VSC, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA (2016) Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord 31:530–537PubMedPubMedCentralCrossRef
218.
Fernandez HH, Standaert DG, Hauser RA, et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509PubMedCrossRef
219.
Amjad F, Bhatti D, Davis TL, Oguh O, Pahwa R, Kukreja P, Zamudio J, Metman LV (2019) Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States. Adv Ther 36:2233–2246PubMedPubMedCentralCrossRef
220.
221.
Modi NB, Mittur A, Dinh P, Rubens R, Gupta S (2019) Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. Clin Neuropharmacol 42:149–156PubMedPubMedCentralCrossRef
222.
Modi NB, Mittur A, Rubens R, Khanna S, Gupta S (2019) Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. Clin Neuropharmacol 42:4–8PubMedCrossRef
223.
Giladi N, Caraco Y, Gurevich T, Djaldetti R, Adar L, Rachmilewitz Minei T, Oren S ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD - MDS Abstracts. Mov Disord 32
224.
Poewe W, Stocchi F, Simuni T, Ellenbogen A, Leionen M, Rachmileqitz Mineu T, Case R, Kieburtz K, Olanow CW (2018) A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety and tolerability of 2 dosing regimens of ND0612
225.
Rosebraugh M, Kym P, Liu W, Facheris M, Benesh J (2019) A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson’s Disease (P3.8-037). Neurology 92
226.
227.
Grosset D, European PD Therapy Compliance Study Group (2010) Therapy adherence issues in Parkinson’s disease. J Neurol Sci 289:115–118PubMedCrossRef
228.
Grosset D, Antonini A, Canesi M, et al (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832PubMedCrossRef
229.
LeWitt PA, Fahn S (2016) Levodopa therapy for Parkinson disease: A look backward and forward. Neurology 86:S3–12PubMedCrossRef
230.
Nijhuis FAP, van den Heuvel L, Bloem BR, Post B, Meinders MJ (2019) The Patient’s Perspective on Shared Decision-Making in Advanced Parkinson's Disease: A Cross-Sectional Survey Study. Front Neurol 10:896PubMedPubMedCentralCrossRef
Metadata
Title
Medical Management and Prevention of Motor Complications in Parkinson’s Disease
Authors
Stephen D. Aradi
Robert A. Hauser
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Neurotherapeutics / Issue 4/2020
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-020-00889-4

Other articles of this Issue 4/2020

Neurotherapeutics 4/2020 Go to the issue

Original Article

BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson’s Disease

Original Article

FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson’s Disease

Original Article

Pituitary Adenylate Cyclase-Activating Polypeptide Attenuates Brain Edema by Protecting Blood–Brain Barrier and Glymphatic System After Subarachnoid Hemorrhage in Rats

Original Article

Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton Dynamics

Original Article

IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy

Review

Autonomic Dysfunction in Parkinson’s Disease